Trial Profile

Phase 2 Single Arm Study of Efficacy and Safety of P1101 for Polycythemia Vera (PV) Patients for Whom the Current Standard of Treatment is Difficult to Apply

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ropeginterferon alfa-2b (Primary) ; Aspirin
Indications Polycythaemia vera
Focus Therapeutic Use
Sponsors PharmaEssentia Corporation

Most Recent Events

01 Aug 2022 Results published in the International Journal of Hematology
17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
08 Jun 2022 According to a PharmaEssentia Corporation media release, data from this study will be presented at the European Hematology Associations Hybrid Congress (EHA2022).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com